Mona Shahriari, MD previews Revolutionizing Atopic Dermatitis 2025

As dermatologic science continues to evolve, the Revolutionizing Atopic Dermatitis (RAD) Annual Meeting has emerged as a vital hub for pediatric specialists seeking up-to-date, evidence-driven strategies in the care of young patients with atopic dermatitis.

In recent years, the surge of therapeutic advancements has transformed the landscape of pediatric eczema treatment. With expanding options now available—including targeted biologics and JAK inhibitors—ongoing education has become indispensable for clinicians hoping to translate innovations into age-appropriate, family-centered care.

“Given how the [atopic dermatitis] landscape has changed so dramatically over the last several years,” explained Mona Shahriari, MD, “I think this is a nice time for us to be able to talk about not only the various treatments that we have, but also how do we optimize treatment for patients, by taking those treatments and appropriately giving them to the patients that are in need, and defining what is adequate control, what is that bar for efficacy that we should be reaching for?”

RAD 2024 provided a deep dive into new data from the LEVEL UP initiative, the Measure Up program, and the DELTA studies—findings with growing relevance for pediatric providers. Sessions also addressed the practical realities of managing atopic dermatitis in children and adolescents, including the impact of comorbid allergic conditions, treatment in diverse skin types, and strategies for long-term disease control in school-aged patients.

Shahriari, who will lead a featured session at RAD 2025 in Nashville (June 6–7), emphasized the conference’s role in bridging clinical research with frontline care. “This is about real-world dermatology,” she noted, pointing to RAD’s focus on pragmatic, patient-centered approaches. Pediatric dermatologists and general pediatricians alike benefit from discussions that not only highlight trial outcomes but also explore how to set appropriate treatment goals, manage family expectations, and tailor regimens to the unique needs of children.

As the field continues to expand, RAD remains a critical forum for advancing pediatric dermatology and ensuring that the next generation of patients receives safe, effective, and equitable care.

This video interview initially appeared on our sister publication, HCP Live.

Reference:

Campbell P. MJH Life Sciences Celebrates Acquisition of Revolutionizing Atopic Dermatitis (RAD) Annual Meeting. HCP Live. Published November 11, 2024. Accessed April 9, 2025. https://www.hcplive.com/view/mjh-life-sciences-celebrates-acquisition-of-revolutionizing-atopic-dermatitis-rad-annual-meeting